Photofrin photodynamic therapy for malignant brain tumors

Paul J. Muller M.D.; Brian C. Wilson; Lothar D. Lilge; Victor X.D. Yang; Fred W. Hetzel; Qun Chen; Tim Fullagar; Robert Fenstermaker; Robert Selker; Judith Abrams

doi:10.1117/12.424454

9 April 2001 Photofrin photodynamic therapy for malignant brain tumors

Paul J. Muller M.D., Brian C. Wilson, Lothar D. Lilge, Victor X.D. Yang, Fred W. Hetzel, Qun Chen, Tim Fullagar, Robert Fenstermaker, Robert Selker, Judith Abrams

Author Affiliations +

Proceedings Volume 4248, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X; (2001) https://doi.org/10.1117/12.424454
Event: BiOS 2001 The International Symposium on Biomedical Optics, 2001, San Jose, CA, United States

Abstract

In a phase II trial we treated more than 100 patients with malignant brain tumors with 2-mg/kg Photofrin iv. and intraoperative cavitary PDT. We concluded that PDT was safe in patients with newly diagnosed or recurrent supratentorial malignant gliomas. Regression analysis showed that pathology, performance grade and light dose were significantly related to survival time. We identified a prolongation of survival in selected patients when an adequate light dose was used. The surgical mortality rate was less than 3%. We have initiated two randomized prospective trials - the first, to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm2] is superior to low light dose PDT [40 J/cm2] in patients with recurrent malignant astrocytic tumors. In the first 20 months of these clinical studies, 90 patients have been recruited. There were 52 in the recurrent study and 37 in the newly diagnosed study. 64% of the tumors were glioblastoma and 23% malignant astrocytoma or malignant mixed glioma. In the trial of newly diagnosed tumors 17 were randomized to surgery with a mean age of 58 ! 2.9 [sem] and 20 to surgery plus PDT with a mean age of 54 ! 2.5. In recurrent glioma trial 26 were randomized to low light dose PDT [mean age 48.1 ! 2.7] and 26 to high light dose [age 52 ! 2.7]. An update of our phase 2 data and a description of brain tumor PDT techniques is presented below. The clinical studies are supported in part by grant CA 43892 awarded by DHHS/NIH/NCI.

Citation Download Citation

Paul J. Muller M.D., Brian C. Wilson, Lothar D. Lilge, Victor X.D. Yang, Fred W. Hetzel, Qun Chen, Tim Fullagar, Robert Fenstermaker, Robert Selker, and Judith Abrams "Photofrin photodynamic therapy for malignant brain tumors", Proc. SPIE 4248, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X, (9 April 2001); https://doi.org/10.1117/12.424454

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available